Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Bolt Biotherapeutics (BOLT) EBITDA (2020 - 2025)

Bolt Biotherapeutics' EBITDA history spans 6 years, with the latest figure at -$7.1 million for Q3 2025.

  • For Q3 2025, EBITDA rose 52.11% year-over-year to -$7.1 million; the TTM value through Sep 2025 reached -$42.9 million, up 33.71%, while the annual FY2024 figure was -$63.1 million, 7.6% up from the prior year.
  • EBITDA for Q3 2025 was -$7.1 million at Bolt Biotherapeutics, up from -$8.6 million in the prior quarter.
  • Across five years, EBITDA topped out at -$7.1 million in Q3 2025 and bottomed at -$27.4 million in Q4 2021.
  • The 5-year median for EBITDA is -$18.1 million (2023), against an average of -$18.2 million.
  • The largest annual shift saw EBITDA plummeted 183.67% in 2021 before it surged 59.41% in 2025.
  • A 5-year view of EBITDA shows it stood at -$27.4 million in 2021, then surged by 30.0% to -$19.2 million in 2022, then grew by 7.89% to -$17.7 million in 2023, then increased by 9.31% to -$16.0 million in 2024, then skyrocketed by 55.45% to -$7.1 million in 2025.
  • Per Business Quant, the three most recent readings for BOLT's EBITDA are -$7.1 million (Q3 2025), -$8.6 million (Q2 2025), and -$11.1 million (Q1 2025).